
Dendreon Corporation (Nasdaq: DNDN) announced that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial designed to asse
Click here for full Story http://www.medicalnewstoday.com/articles/124389.php |